Publications by authors named "Lara N Monkiewicz"
Background: Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within CHAPAS-4 to evaluate darunavir exposure in African children with HIV, taking once-daily darunavir/ritonavir for second-line treatment.
Methods: We used data from the CHAPAS-4 pharmacokinetic sub-study treating children with once-daily darunavir/ritonavir (600/100 mg if 14-24.
Article Synopsis
- Dolutegravir (DTG) is metabolized in the body, producing an inactive form called DTG glucuronide (DTG-gluc), and the study focused on its metabolic ratio (DTG-MR) among 85 HIV-positive children aged 3 months to 18 years.
- The research found that the overall DTG-MR in children was similar to that in adults and was primarily influenced by the use of rifampicin, which significantly increased the DTG-MR.
- These results suggest that factors like age, body weight, and type of NRTI treatment do not affect the DTG-MR in children, paving the way for better pharmacokinetic modeling for pediatric patients based on adult data
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Hylke Waalewijn Alexander J Szubert Roeland E Wasmann Lubbe Wiesner Chishala Chabala Lara N Monkiewicz
Clin Infect Dis
September 2023
Article Synopsis
- * Children were divided into groups to receive either emtricitabine/TAF or standard HIV treatments, with doses determined by their weight, and blood samples were analyzed for drug concentration.
- * Results showed that TAF levels in children were similar to those seen in adults, suggesting these treatments are effective and safe for young patients in Africa.